. Baseline characteristics of propensity matched patients in the Serum Creatinine Measurements (SCREAM) cohort who initiated ACE-I or ARB therapy and those who initiated beta blocker therapy who were not on ACE-I or ARB therapy Potassium > 5.5mmol/L, n (%) 197 (1.3%) 173 (1.4%) Abbreviations: SD, standard deviation; CHF, congestive heart failure; CAD, coronary artery disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; NSAID, non-steroidal anti-inflammatory drug; K, potassium; HTN, hypertension; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker therapy; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio. Indication for ACE-I/ARB defined as ACR ≥300 mg/g or a protein level of ++ on urine dipstick, a diagnosis of congestive heart failure, or a diagnosis of diabetes mellitus with ACR >30 mg/g or a protein level of + on urine dipstick. Abbreviations: SD, standard deviation; CHF, congestive heart failure; CAD, coronary artery disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; NSAID, non-steroidal anti-inflammatory drug; K, potassium; HTN, hypertension; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker therapy; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio. Indication for ACE-I/ARB defined as ACR ≥300 mg/g or a protein level of ++ on urine dipstick, a diagnosis of congestive heart failure, or a diagnosis of diabetes mellitus with ACR >30 mg/g or a protein level of + on urine dipstick. 
